Advances and Challenges in Anticancer Drug Therapy: A Comprehensive Review

Mr. Hemant Sunil Mali[1], Mr. Akshay Bhangare[2], Ms. Yagya Dadhich[3], Ms. Ashwini Pandhari Pattewad[4]. Ms. Shital Kailas Patil[5].

[1]*Research Scholar & Assistant Professor at Ahinsa Institute of Pharmacy Dondaicha, Shindkhedha, Dhule, (M.S), India, 425408.*

[2]*Research Scholar at Bombay college of pharmacy, Mumbai, (M.S), India, 400098.*

[3]*Research Scholar at Noida Institute of Engineering and Technology NIET-Pharmacy Institute, Gautam Buddha Nagar, Greater Noida, (U.P), India, 201306.*

[4]*Reasearch Scholar at Rajashri Shahu college of Pharmacy, Markhel, Degloor, Nanded, (M.S), India, 431718.*

[5]*Assistant Professor at Hon. T. S. Baviskar Institute of Pharmaceutical Education & research, Dahiwad, Shirpur Dhule, (M.S), India, 425405.*

***Abstract*—This review explores the current landscape of anticancer drug therapies, outlining their classifications, mechanisms of action, and the progression of treatment strategies. It highlights the shift from() conventional chemotherapeutic agents toward advanced modalities such as targeted therapies, immunotherapies, monoclonal antibodies, tyrosine kinase inhibitors, hormone-based treatments, CAR-T cell therapy, and nanotechnology-enabled drug delivery systems. These therapeutic approaches function through diverse mechanisms, including induction of apoptosis, DNA damage, angiogenesis inhibition, and modulation of the cell cycle. Despite remarkable advancements, significant challenges remain, particularly in overcoming drug resistance, ensuring equitable global access to therapies, and optimizing dosing and targeting for personalized treatment. Emphasis is placed on molecular targeting strategies, innovations in drug delivery systems, and addressing resistance mechanisms. Emerging directions include the integration of genomic profiling for individualized treatment, refinement of delivery platforms, and coordinated global efforts to reduce disparities in cancer care. Ultimately, this review underscores the importance of continuous innovation and equitable access to modern cancer therapies to improve patient outcomes worldwide.**

***Index Terms*—Anticancer drug therapies, chemotherapeutic agents, targeted therapies, immunotherapies**

1. INTRODUCTION

Cancer remains one of the most pressing global health concerns, with wide-ranging effects on individuals, families, and societies. Although advances have been made in prevention, early detection, and treatment, the disease continues to impose a heavy burden on healthcare systems worldwide. A major challenge lies in the unequal access to modern cancer care, largely due to the lack of standardized approaches for delivering high-quality treatment across different regions. To address these gaps, various global initiatives and organizations have been established with the aim of improving cancer care and ensuring equitable access to treatment.

Currently, cancer stands as one of the leading causes of morbidity and mortality worldwide, responsible for approximately 5.5 million deaths annually, a figure projected to rise to 8.9 million by 2030 (Kawahara et al., 2010; Cancer, 2023) [6, 22, 45]. This burden is particularly severe in low- and middle-income countries, where fragile healthcare infrastructures often limit access to effective prevention, diagnostic services, and treatment options ("Cancer", 2023) [22, 45]. This review provides an overview of cancer's epidemiology, its impact on public health, and ongoing global efforts to manage it as a critical health challenge.

With aging populations and lifestyle factors such as tobacco use and unhealthy diets, the incidence of cancer continues to rise. Importantly, the disease disproportionately affects populations in resource-limited settings, where disparities in healthcare access and outcomes are most evident (Jackman et al., 2024) [19]. Beyond its direct health implications, cancer has far-reaching consequences, straining families, communities, and healthcare systems. Effective cancer control therefore requires comprehensive strategies that integrate prevention, early detection, and universal access to care.

Universal health coverage plays a vital role in achieving effective cancer control ("Cancer", 2023) [22, 45]. Numerous initiatives worldwide are focused on standardizing cancer care and expanding access to treatment, particularly in underserved regions. Collaboration among healthcare professionals and communities is equally important to raise awareness and improve cancer-related knowledge ("Cancer", 2023) [22, 45]. Despite these advancements, significant gaps remain in terms of accessibility, especially in resource-limited settings. Given the complex and multifactorial nature of cancer, continuous research and international cooperation are essential to achieve better treatment outcomes in the future.

Pharmacologic therapy is a cornerstone of cancer management, addressing needs that range from symptom relief to advanced molecularly targeted interventions. Its role extends beyond supportive care to providing systemic treatment for malignant cells throughout the body, complementing surgery and radiation therapy. Traditional chemotherapy continues to serve as a first-line option; however, breakthroughs in molecular biology have introduced immunotherapies and biologics, which now form an integral part of contemporary oncology practice (Pont et al., 2021) [38, 61].

Drug-based therapy is indispensable because it enables precise modulation of cancer pathways while minimizing unintended side effects. Advances in genomics and transcriptomics allow treatments to be tailored to individual patients, maximizing therapeutic efficacy. Additionally, real-time molecular imaging technologies, such as PET and MRI, have enhanced monitoring of drug distribution and uptake. Innovative delivery systems—such as liposomes and antibody-drug conjugates—are also being developed to improve efficacy and reduce systemic toxicity, further reinforcing the central role of pharmacotherapy in modern oncology (Asif, 2023) [2].

Although surgery and radiotherapy remain frontline treatment modalities, pharmacotherapy, particularly chemotherapy, has historically been the foundation of systemic cancer treatment. Deeper insights into cancer biology have paved the way for novel therapeutic options, including immunotherapy and targeted biologics. These newer agents are often employed either as standalone therapies or in combination with chemotherapy, significantly improving outcomes for the most prevalent cancers, such as those affecting the lung, breast, prostate, colon, and skin (Gundy & Nguyen, 2017; Pont et al., 2021) [15].

The objective of this review is to critically examine both the progress and challenges in anticancer drug therapy. Given that cancer remains one of the leading causes of death worldwide, the development of effective and highly specific therapeutic strategies is essential. This work explores advances in anticancer drugs ranging from conventional chemotherapeutic agents to next-generation targeted therapies, immunotherapies, and cutting-edge approaches such as gene therapy and nanotechnology-based drug delivery systems.

2. CLASSIFICATION OF ANTICANCER DRUGS

Anticancer agents can be classified in multiple ways due to the diversity in their mechanisms and therapeutic targets. A two-tiered system proposed in recent studies organizes them according to the site of action—such as tumor vasculature, immune system, endocrine system, or tumor cells—and their molecular targets (Ostios-García et al., 2024) [35, 58]. Additionally, pharmacological categorization uses chromatographic and chemometric data, such as lipophilicity and molecular descriptors, to predict biological activity (Gackowski et al., 2021) [13]. Plant-derived compounds also constitute a significant portion of anticancer agents, which can be broadly grouped into four classes: DNA-damaging/pro-oxidant drugs, methyltransferase inhibitors, mitotic disruptors, and HDAC inhibitors (Amin et al., 2009) [1].

Overall, anticancer drugs can be classified by site of action, mechanism of action, chemical origin, pharmacological properties, and molecular targeting strategy. This multidimensional classification system is useful in analyzing therapeutic roles and clinical applications.

2.1 Site and Mechanism of Action

Anticancer drugs act on different biological systems including tumor cells, tumor vasculature, the immune system, and the endocrine system. They work by interfering with molecular pathways or structural components at these sites (Ostios-García et al., 2024) [35, 58]. For example, alkylating agents cross-link DNA to block replication and transcription, while antimetabolites mimic essential biomolecules to disrupt DNA and RNA synthesis (Ogawa, 1997).

2.2 Chemical Origins

Another method of classification is based on drug sources: synthetic compounds, natural products, or derivatives of natural molecules**.** Plant-derived agents are particularly important due to their wide availability and relatively low toxicity (Amin et al., 2009) [1]. Examples include **plant alkaloids**, which inhibit microtubule formation, and **camptothecins**, which block topoisomerase I (Ogawa, 1997) [34, 57].

2.3 Pharmacological Properties

Pharmacological classification involves analyzing physicochemical properties such as lipophilicity and molecular descriptors to predict therapeutic activity. Techniques like chromatography and chemometric modeling are applied to categorize drugs on this basis (Gackowski et al., 2021) [13]. However, the emergence of drugs with novel mechanisms of action continues to challenge traditional classifications. This highlights the need for an adaptive system that accommodates evolving therapies (Chen et al., 2024) [9].

2.4 Molecular Targeting

Based on molecular targeting, anticancer drugs are broadly grouped into conventional chemotherapy **and** targeted therapy.

- 2.4.1 Conventional Chemotherapy
  - Mechanism: Cytotoxic agents act on all rapidly dividing cells, both malignant and healthy, leading to systemic toxicity.
  - Examples: Alkylating agents, antimetabolites, topoisomerase inhibitors (Ostios-García et al., 2024) [35, 58].
  - Adverse Effects: Common side effects include nausea, alopecia, and immunosuppression (Keefe & Stringer, 2010) [23, 46].

- 2.4.2 Targeted Therapy
  - Mechanism: Targets specific molecular pathways or receptors involved in cancer growth, such as EGFR or VEGFR.
  - Examples: Monoclonal antibodies, small-molecule tyrosine kinase inhibitors (Bicknell, 2005).
  - Advantages: More selective, sparing normal cells, thus reducing side effects (Keefe & Stringer, 2010) [23, 46].
  - Limitations: Resistance mechanisms and patient selection remain significant challenges (Min & Lee, 2022) [54, 31].

- 2.4.3 Cell Cycle Specificity
  Anticancer agents exploit dysregulated proliferation in tumor cells by targeting specific cell cycle phases. For example:
  - Adriamycin (ADR), Etoposide (VP16): Act during the S-phase.
  - Prednisone (PRD): Active in the G1 phase. Advances in high-throughput screening have enabled identification of drugs with selective activity at different cell cycle checkpoints (Bai et al., 2017; Johnson et al., 2021) [20, 36, 59].
- 2.4.4 Mechanistic Pathways: Apoptosis, DNA Damage, and Angiogenesis Inhibition
  - Apoptosis Induction: Cisplatin triggers caspase activation; Doxorubicin induces ROS; signaling pathways such as c-Jun/AP-1 regulate apoptosis in resistant cells (Havelka et al., 2007; Kim et al., 2024) [16, 24, 47].
  - DNA Damage: Agents like doxorubicin and cisplatin cause oxidative DNA damage, leading to cell cycle arrest and apoptosis. Concentration-dependent effects determine whether apoptosis or cytotoxicity predominates (Mizutani, 2008; Havelka et al., 2007) [16, 32, 55].
  - Angiogenesis Inhibition: Certain drugs prevent tumor growth by blocking blood vessel formation, depriving tumors of oxygen and

nutrients. While apoptosis is a major therapeutic goal, some antitumor responses are independent of DNA damage, suggesting alternative mechanisms also contribute (Havelka et al., 2007; Berndtsson, 2007) [16].

3.1 Monoclonal Antibodies (continued)

b. Rituximab

- Target: CD20 antigen
- Indication: Non-Hodgkin lymphomas and chronic lymphocytic leukemia
- Mechanism: Rituximab triggers apoptosis and facilitates immune effector cell recruitment. It remains a cornerstone in hematological malignancy therapy and continues to evolve through biosimilar versions and antibody–drug conjugates (ADCs) (Cramer et al., 2021) [10].

3.2 Tyrosine Kinase Inhibitors (TKIs)

TKIs are small-molecule drugs that interfere with intracellular phosphorylation cascades, thereby inhibiting cancer cell growth and survival.

- a. Imatinib
  - Target: BCR-ABL fusion protein
  - Cancer: Chronic myeloid leukemia (CML)
  - Mechanism: Selectively inhibits the ABL kinase domain. Imatinib transformed CML from a fatal disease into a manageable condition, marking the beginning of precision oncology (Hochhaus et al., 2020) [18].

- b. Erlotinib
  - Target: Epidermal Growth Factor Receptor (EGFR)
  - Cancer: Non-small cell lung cancer (NSCLC)
  - Mechanism: Blocks EGFR tyrosine kinase activity, particularly effective in tumors with EGFR-activating mutations. Erlotinib and other EGFR-directed TKIs are standard treatments for EGFR-mutant NSCLC, though resistance mutations such as T790M are common (Zhang et al., 2021) [3].

3.3 Immunotherapy

Immunotherapy with checkpoint inhibitors restores the ability of the immune system to recognize and destroy malignant cells, revolutionizing cancer treatment across multiple tumor types.

- a. PD-1/PD-L1 Inhibitors
  - Examples: Pembrolizumab, Nivolumab, Atezolizumab
  - Mechanism: Block PD-1 receptors or their ligand PD-L1, revitalizing exhausted T-cells. These agents have shown durable responses in melanoma, NSCLC, and urothelial carcinoma (Ribas & Wolchok, 2018) [39, 62].
- b. CTLA-4 Inhibitors
  - Example: Ipilimumab
  - Mechanism: Promotes T-cell activation by blocking CTLA-4 inhibitory signaling. Combined PD-1 and CTLA-4 blockade offers superior outcomes in advanced melanoma, albeit with higher toxicity levels (Weber et al., 2021) [44, 67].

3.4 CAR-T Cell Therapy

Chimeric Antigen Receptor T-cell (CAR-T) therapy involves engineering a patient's T-cells with genetic modifications that enable them to recognize and attack tumor antigens.

- Examples: Tisagenlecleucel, Axicabtagene ciloleucel
- Indications: B-cell acute lymphoblastic leukemia, large B-cell lymphoma
- Mechanism: Redirects modified T-cells to identify and destroy malignant cells. CAR-T therapy has demonstrated curative potential in refractory hematologic cancers, though barriers such as high cost, complex manufacturing, and limited efficacy in solid tumors remain (June & Sadelain, 2018) [21].

3.5 Hormone Therapy

Hormonal manipulation is particularly effective in breast and prostate cancers that depend on hormone signaling for growth.

- a. Tamoxifen
  - Class: Selective Estrogen Receptor Modulator (SERM)
  - Indication: Estrogen receptor-positive (ER+) breast cancer
  - Mechanism: Blocks estrogen receptors in breast tissue. Tamoxifen has been a gold-standard therapy for decades, particularly in premenopausal women (EBCTCG, 2019).
    - b. Aromatase Inhibitors
  - Examples: Anastrozole

- Mechanism: Inhibit aromatase, lowering estrogen levels in postmenopausal women. Aromatase inhibitors are superior to tamoxifen in preventing recurrence among postmenopausal breast cancer patients (Burstein et al., 2019) [5].

4. DRUG RESISTANCE IN CANCER THERAPY

Drug resistance remains one of the most critical barriers to successful cancer treatment. While initial responses may be favorable, many tumors relapse or progress due to adaptive mechanisms. Resistance can be intrinsic (present before treatment) or acquired (emerging during therapy) and is shaped by genetic, epigenetic, and microenvironmental factors.

4.1 Intrinsic vs. Acquired Resistance

- Intrinsic Resistance: Occurs when tumors inherently lack sensitivity, such as triple-negative breast cancers that lack ER/PR receptors and are unresponsive to hormonal therapy.
- Acquired Resistance: Develops over time due to mutations, clonal selection, or cellular plasticity. For instance, NSCLC patients treated with EGFR inhibitors often acquire resistance via secondary mutations such as T790M (Chatterjee et al., 2021) [5].

4.2 Molecular Mechanisms of Resistance

- a. Efflux Pumps: Overexpression of ATP-binding cassette (ABC) transporters like P-glycoprotein (ABCB1) and MRP1 (ABCC1) lowers intracellular drug concentrations, reducing efficacy of agents such as doxorubicin, paclitaxel, and vincristine. Attempts to block these pumps face toxicity and redundancy challenges.
- b. Target Gene Mutations: Mutations in target proteins (e.g., EGFR T790M, BCR-ABL T315I, KRAS) reduce drug binding. Similarly, resistance to checkpoint inhibitors can occur through JAK1/2 mutations disrupting interferon signaling (McCoach et al., 2020).
- c. Enhanced DNA Repair: Resistance to DNA-damaging drugs (e.g., platinum agents, PARP inhibitors) may arise from reactivation of DNA repair pathways. BRCA-mutated tumors can develop resistance through reversion mutations or improved homologous recombination repair, necessitating combination approaches (Liu et al., 2022) [27].

4.3 Role of the Tumor Microenvironment (TME)

The TME, comprising stromal and immune cells, cytokines, and extracellular matrix, plays a vital role in resistance. Hypoxia, for example, promotes angiogenesis and resistance through HIF-1α. Cancer-associated fibroblasts (CAFs) remodel the extracellular matrix, while immunosuppressive cells (Tregs, MDSCs) impair the efficacy of immunotherapies. Strategies such as vascular normalization and immune modulation are actively under clinical investigation (Hinshaw & Shevde, 2019) [17].

5. SIDE EFFECTS AND TOXICITY OF ANTICANCER DRUGS

Although effective, anticancer drugs often produce toxicities that impact both short-term function and long-term quality of life (QoL). Toxicities depend not only on the therapy type (chemotherapy, targeted therapy, immunotherapy) but also on patient-specific factors such as age, comorbidities, and genetic profile.

5.1 Common Acute Side Effects

- Nausea & Vomiting: Frequently caused by agents such as cisplatin, doxorubicin, and cyclophosphamide. Modern antiemetic regimens (NK1 antagonists, 5-HT3 antagonists, corticosteroids) have reduced incidence significantly (Navari & Aapro, 2016) [33].
- Alopecia: Common with taxanes and anthracyclines. Although reversible, it can be psychologically distressing. Scalp cooling devices mitigate chemotherapy-induced alopecia (Rugo et al., 2017) [40].
- Bone Marrow Suppression: A dose-limiting effect of many cytotoxic agents (platinums, alkylating drugs), leading to neutropenia, anemia, and thrombocytopenia. Supportive measures include growth factors (e.g., G-CSF) and dose adjustments (Smith et al., 2015) [42].

5.2 Long-Term Toxicities

- Cardiotoxicity: Anthracyclines and HER2-targeted therapies (e.g., trastuzumab) can cause heart dysfunction, ranging from reduced ejection fraction to irreversible heart failure. Up to 20%

of treated patients may develop cardiac issues within five years.

- Neurotoxicity: Includes peripheral neuropathy (taxanes, platinums), cognitive decline ("chemo brain"), and CNS toxicity (high-dose methotrexate). These effects can persist for years and severely impair daily functioning (Lavoie Smith et al., 2019) [19].

5.3 Quality of Life (QoL) Considerations

Beyond physical symptoms, cancer treatments affect fatigue, mood, sleep, and daily functioning. Incorporating patient-reported outcomes (PROs) in clinical trials has improved real-world evaluation of treatment impact. Supportive interventions such as nutritional therapy, psychological care, and rehabilitation services are crucial. While targeted agents and immunotherapies reduce some side effects compared to chemotherapy, they also introduce new immune-related toxicities that affect QoL (Basch et al., 2017) [4].

6. STRATEGIES TO OVERCOME LIMITATIONS IN CANCER THERAPY

Despite significant progress, cancer treatment continues to face challenges such as resistance, toxicity, and tumor heterogeneity. To address these issues, modern oncology emphasizes multi-modal therapy, personalized medicine, and innovative drug delivery technologies.

6.1 Combination Therapy

Combination regimens integrate agents with distinct mechanisms to maximize efficacy and delay resistance. Classic examples include FOLFOX for colorectal cancer and trastuzumab with paclitaxel in HER2+ breast cancer. More recently, combinations such as chemotherapy with immunotherapy (e.g., pembrolizumab plus platinum chemotherapy in NSCLC) are widely used. Although effective, these regimens require careful management of additive toxicities (Vasan et al., 2019) [43].

6.2 Personalized Medicine and Pharmacogenomics

Personalized treatment uses genomic and molecular profiling to adapt therapies to individual tumor characteristics and patient genetics. Pharmacogenomic insights help predict drug metabolism and response (e.g., TPMT with 6-mercaptopurine, UGT1A1 with irinotecan). Next-generation sequencing (NGS) enables detection of actionable mutations (EGFR, ALK, BRAF), guiding precise targeted therapies. This approach minimizes trial-and-error, enhances outcomes, and reduces adverse events (Dienstmann et al., 2018) [11].

6.3 Nanotechnology in Drug Delivery

Nanotechnology has revolutionized cancer therapeutics by enabling the development of nanoscale carriers, including liposomes, dendrimers, and polymeric nanoparticles. These systems enhance tumor-specific targeting, improve solubility of poorly water-soluble agents, reduce systemic toxicities, and allow controlled drug release. Clinically approved nanodrugs such as Doxil® (liposomal doxorubicin) and Abraxane® (albumin-bound paclitaxel) have demonstrated superior tolerability and selective accumulation in tumors. Current research is moving toward "smart nanocarriers" that respond to tumor microenvironment stimuli (e.g., pH, enzymes), enabling localized and more precise drug release (Kirtane et al., 2021) [21].

6.4 Biomarker-Guided Therapy

Biomarkers are increasingly being applied as predictive and prognostic tools to optimize cancer treatment. Examples include PD-L1 expression for checkpoint inhibitor response, BRCA1/2 mutations for predicting PARP inhibitor sensitivity, and MSI-high/dMMR status for responsiveness to immunotherapies in colorectal and endometrial cancers. Large-scale clinical trials such as NCI-MATCH and TAPUR exemplify the implementation of biomarker-driven, precision-guided therapies (Meric-Bernstam et al., 2021) [30].

7. EMERGING TRENDS AND FUTURE DIRECTIONS IN ANTICANCER DRUG DEVELOPMENT

Advances in molecular biology, computational sciences, and genetic engineering have ushered in a new era of anticancer drug discovery. Current innovations emphasize improving therapeutic efficacy, increasing precision, minimizing toxicities, and tackling cancers previously deemed "undruggable."

7.1 Novel Drugs and Small Molecules

The drug development pipeline now includes small-molecule inhibitors against targets once thought intractable, such as KRAS G12C mutations. Agents like sotorasib (AMG 510) and adagrasib (MRTX849)

have shown promising outcomes in NSCLC and colorectal cancers (Canon et al., 2019) [7]. Additionally, Proteolysis-targeting chimeras (PROTACs) provide an innovative approach by degrading, rather than inhibiting, proteins, thus bypassing resistance mechanisms and expanding the therapeutic spectrum (Pettersson & Crews, 2019) [37].

7.2 Artificial Intelligence in Drug Discovery

Artificial Intelligence (AI) is reshaping drug development by predicting drug–target interactions, optimizing lead compounds, designing new molecules, and repurposing existing drugs. Tools such as AlphaFold have significantly improved protein structure prediction, which is essential for rational drug design. AI-driven strategies reduce the time and cost of developing novel anticancer agents, accelerating the identification of promising drug candidates.

7.3 Gene-Editing and CRISPR-Based Strategies

CRISPR-Cas9 and related gene-editing tools hold significant promise in both cancer research and therapy. High-throughput CRISPR screens are being used to uncover novel cancer vulnerabilities and therapeutic targets. Clinically, CRISPR-modified T-cells are being tested for enhanced immune targeting of tumors, particularly in refractory cancers (Lu et al., 2020) [28]. These approaches may allow gene correction, synthetic lethality-based therapies, and immune system reprogramming with high precision.

7.4 Cancer Vaccines and Preventive Therapies

Cancer vaccines are emerging as both preventive and therapeutic tools. Building upon the success of mRNA vaccine platforms in infectious diseases, novel mRNA-based vaccines are under investigation for cancers such as melanoma, lung, and colorectal cancers (Sahin et al., 2020) [41]. Personalized neoantigen vaccines, tailored to each patient's tumor-specific mutations, are in clinical development and aim to elicit long-lasting, highly specific immune responses to reduce recurrence risk.

8. CONCLUSION

Over the past decades, cancer therapeutics have advanced from broadly cytotoxic chemotherapies to precision-guided molecular agents and immunotherapies. Integrating genomics, proteomics, and bioinformatics has enabled the design of drugs that better exploit tumor biology while sparing healthy tissues.

Despite progress, key challenges persist—including intrinsic and acquired resistance, tumor heterogeneity, immune evasion, treatment-related toxicity, and inequitable global access to advanced therapies. Addressing these barriers requires multidisciplinary collaboration among oncologists, pharmacologists, molecular scientists, and bioengineers. Ensuring affordability and accessibility must remain central to progress.

The outlook for cancer therapy is promising, with AI-powered drug discovery, CRISPR-based interventions, nanotechnology, and biomarker-driven precision oncology paving the way for safer, more effective, and durable treatments. These developments are not only extending survival but also improving the quality of life for patients worldwide.

REFERENCES

[1] Amin A, Gali-Muhtasib H, Ocker M, Schneider-Stock R. Overview of major classes of plant-derived anticancer drugs. Int J Biomed Sci. 2009;5(1):1-11. Available from: http://ijbs.org/user/ContentFullText.aspx?VolumeNO=5&StartPage=1&Type=pdf

[2] Asif Q ul A. Cancer pharmacology advances: fundamentals, combination, imagery, shipment and therapeutic applications. 2023. Available from: https://doi.org/10.18782/2582-2845.9030

[3] Bai JW, Li YC, Zhang GJ. Cell cycle regulation and anticancer drug discovery. Cancer Biol Med. 2017;14(4):348-62. Available from: https://doi.org/10.20892/J.ISSN.2095-3941.2017.0033

[4] Basch E, Deal AM, Kris MG, Scher HI, Hudis CA, Sabbatini P, et al. Symptom monitoring with patient-reported outcomes during routine cancer treatment: a randomized controlled trial. J Clin Oncol. 2017;35(6):557-65. Available from: https://doi.org/10.1200/JCO.2016.69.5946

[5] Burstein HJ, et al. Endocrine treatment of hormone receptor-positive, HER2-negative breast cancer: ASCO guideline. J Clin Oncol. 2019;37(30):3141-66. Available from: https://doi.org/10.1200/JCO.19.00992

[6] Cancer. In: Routledge eBooks. 2023. p. 83-90. Available from: https://doi.org/10.4324/9781003306689-13

[7] Canon J, Rex K, Saiki AY, Mohr C, Cooke K, Bagal D, et al. The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity. Nature. 2019;575(7781):217-23. Available from: https://doi.org/10.1038/s41586-019-1694-1

[8] Chatterjee N, Bivona TG, Sequist LV. Mechanisms of resistance to EGFR inhibitors in non-small cell lung cancer: emerging concepts and clinical implications. Nat Rev Cancer. 2021;21(9):645-61. Available from: https://doi.org/10.1038/s41568-021-00369-9

[9] Chen X, Ou S, Luo J, He Z, Jiang Q. Advancing perspectives on the off-label use of anticancer drugs: an updated classification and exploration of categories. Front Pharmacol. 2024; 15:1374549. Available from: https://doi.org/10.3389/fphar.2024.1374549

[10] Cramer P, et al. Advances in CD20-targeting therapies for B-cell malignancies. Lancet Oncol. 2021;22(5):e202-13. Available from: https://doi.org/10.1016/S1470-2045(21)00060-3

[11] Dienstmann R, Vermeulen L, Guinney J, Kopetz S, Tejpar S, Tabernero J. Consensus molecular subtypes and the evolution of precision medicine in colorectal cancer. Nat Rev Cancer. 2018;17(2):79-92. Available from: https://doi.org/10.1038/nrc.2017.77

[12] Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Tamoxifen for early breast cancer: 10-year survival results. Lancet. 2019;393(10190):1683-97. Available from: https://doi.org/10.1016/S0140-6736(18)32897-7

[13] Gackowski M, Koba M, Pluskota R, Daghir-Wojtkowiak E, Szatkowska-Wandas P, Kruszewski S. Pharmacological classification of anticancer drugs applying chromatographic retention data chemometric analysis. Chem Pap. 2021;75(1):265-78. Available from: https://doi.org/10.1007/S11696-020-01301-3

[14] Gianni L, et al. 20-year update of trastuzumab-based therapy in HER2-positive breast cancer. N Engl J Med. 2022;387(2):113-25. Available from: https://doi.org/10.1056/NEJMoa2203465

[15] Gundy JT, Nguyen M. Cancer pain: pharmacological treatment. In: Gundy JT, Nguyen M, editors. Cancer. Springer; 2017. p. 441-3. Available from: https://doi.org/10.1007/978-3-319-43133-8_115

[16] Havelka A, Berndtsson M, Olofsson MH, Shoshan MC, Linder S. Mechanisms of action of DNA-damaging anticancer drugs in treatment of carcinomas: is acute apoptosis an “off-target” effect? Mini-Rev Med Chem. 2007;7(10):1035-9. Available from: https://doi.org/10.2174/138955707782110196

[17] Shevde LA. The tumor microenvironment innately modulates cancer progression. Cancer Res. 2019;79(18):4557-62. Available from: https://doi.org/10.1158/0008-5472.CAN-18-3962

[18] Hochhaus A, et al. Long-term outcomes of imatinib therapy for chronic myeloid leukemia. Leukemia. 2020;34(4):1134-44. Available from: https://doi.org/10.1038/s41375-019-0705-2

[19] Jackman JM, Yibrehu B, Doyle A, Alatise OI, Wuraola F, Olasehinde O, et al. Updates in global oncology: advancements and future directions. J Surg Oncol. 2024. Available from: https://doi.org/10.1002/jso.27633

[20] Johnson TI, Minteer CJ, Kottmann D, Dunlop CR, Bernaldo de Quirós Fernández S, Carnevalli LS, et al. Quantifying cell cycle-dependent drug sensitivities in cancer using a high throughput synchronisation and screening approach. EBioMedicine. 2021; 68:103396. Available from: https://doi.org/10.1016/J.EBIOM.2021.103396

[21] June CH, Sadelain M. Chimeric antigen receptor therapy. N Engl J Med. 2018;379(1):64-73. Available from: https://doi.org/10.1056/NEJMra1706169

[22] Kawahara N, Masui T, Roh JK, Hao XS, Hill DE, Akaza H. What should we do to raise awareness on the issue of cancer in the global health agenda. Jpn J Clin Oncol. 2010;40(1):82-5. doi: 10.1093/jjco/hyq132

[23] Keefe DMK, Stringer AM. The potential successes and challenges of targeted anticancer therapies. Curr Opin Support Palliat Care. 2010;4(1):16-8. doi: 10.1097/spc.0b013e3283357619

[24] Kim R, Kin T, Beck WT. Impact of complex apoptotic signaling pathways on cancer cell

sensitivity to therapy. Cancers (Basel). 2024;16(5):984. doi: 10.3390/cancers16050984

[25] Kirtane AR, Kalscheuer SM, Panyam J, Langer R. Nanotechnology for cancer therapy: progress, challenges and opportunities. Nat Rev Drug Discov. 2021;20(3):173-4. doi: 10.1038/d41573-021-00034y

[26] Lavoie Smith EM, Li L, Chiang C, Thomas CM, Hammer MJ. Chemotherapy-induced peripheral neuropathy: a current review. Curr Pain Headache Rep. 2019;23(9):1-9. doi: 10.1007/s11916-019-0802-3

[27] Liu Y, Sun L, Cai L, Lin Z. Mechanisms of resistance to PARP inhibitors and their clinical implications. Front Oncol. 2022;12:875163. doi: 10.3389/fonc.2022.875163

[28] Lu Y, Xue J, Deng T, Zhou X, Yu K, Deng L, et al. Safety and feasibility of CRISPR-edited T cells in patients with refractory non-small-cell lung cancer. Nat Med. 2020;26(5):732-40. doi: 10.1038/s41591-020-0840-7

[29] McCoach CE, Blakely CM, Banks KC, Levy B, Riess JW. Clinical utility of cell-free DNA for the detection of ALK fusions and resistance mutations in ALK-positive lung cancer. J Thorac Oncol. 2020;15(9):1430-42. doi: 10.1016/j.jtho.2020.05.005

[30] Meric-Bernstam F, Brusco L, Daniels M, Wathoo C, Bailey AM. NCI-MATCH and TAPUR: evolving the landscape of precision oncology. Clin Cancer Res. 2021;27(3):665-70. doi: 10.1158/1078-0432.CCR-20-3280

[31] Min H, Lee HY. Molecular targeted therapy for anticancer treatment. Exp Mol Med. 2022;54(10):1670-94. doi: 10.1038/s12276-022-00864-3

[32] Mizutani H. Mechanism of DNA damage and apoptosis induced by anticancer drugs through generation of reactive oxygen species. ChemInform. 2008;39(15):1-6. doi: 10.1002/chin.200815268

[33] Navari RM, Aapro M. Antiemetic prophylaxis for chemotherapy-induced nausea and vomiting. N Engl J Med. 2016;374(14):1356-67. doi: 10.1056/NEJMra1515442

[34] Ogawa M. Anticancer drugs and pharmacologic actions. Nihon Rinsho. Jpn J Clin Med. 1997;55(5):1017-23. Available from: https://pubmed.ncbi.nlm.nih.gov/9155146/

[35] Ostios-García L, Martínez-Pérez D, Castelo B, Hernández Herradón N, Zamora P, Feliú J, et al. Classification of anticancer drugs: an update with FDA and EMA-approved drugs. Cancer Metastasis Rev. 2024;43(1):1-13. doi: 10.1007/s10555-024-10188-5

[36] Patra D, Bhavya K, Kalia M, Pal D. Anti-cancer drug molecules targeting cancer cell cycle and proliferation. In: Advances in Pharmacology and Clinical Toxicology. Vol. 135. Elsevier; 2023. p. 343-95. doi: 10.1016/bs.apcsb.2022.11.011

[37] Pettersson M, Crews CM. PROteolysis TArgeting Chimeras (PROTACs)—past, present and future. Drug Discov Today Technol. 2019;31:15-27. doi: 10.1016/j.ddtec.2019.01.002

[38] Pont LG, Dua K, Cutler RL, Benson H, Hagi M, Cardenas VG, et al. Current practice in cancer pharmacotherapy. In: Cancer Pharmacotherapy. Academic Press; 2021. p. 9-15. doi: 10.1016/B978-0323-85503-7.00040-7

[39] Ribas A, Wolchok JD. Cancer immunotherapy using checkpoint blockade. Science. 2018;359(6382):1350-5. doi: 10.1126/science.aar4060

[40] Rugo HS, Voigt J, Scalp Cooling Alopecia Prevention Study Group. Scalp cooling for the prevention of chemotherapy-induced alopecia. JAMA. 2017;317(6):606-14. doi: 10.1001/jama.2016.20939

[41] Sahin U, Derhovanessian E, Miller M, Kloke BP, Simon P, Löwer M, et al. Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer. Nature. 2020;585(7823):107-13. doi: 10.1038/s41586-020-2537-9

[42] Smith TJ, Bohlke K, Lyman GH, Carson KR, Crawford J, Cross SJ, et al. Recommendations for the use of WBC growth factors: ASCO clinical practice guideline update. J Clin Oncol. 2015;33(28):3199-212. doi: 10.1200/JCO.2015.62.3488

[43] Vasan N, Baselga J, Hyman DM. A view on drug resistance in cancer. Nature. 2019;575(7782):299-309. doi: 10.1038/s41586-019-1730-1

[44] Weber JS, et al. Dual checkpoint blockade in advanced melanoma: 5-year follow-up. J Clin Oncol. 2021;39(17):1866-75. doi: 10.1200/JCO.20.036